New England Pediatric Device Consortium (NEPDC) announced Velano Vascular as the recipient of an award including funding and in-kind service towards the commercialization of the company’s needle free blood draw technology.
“Making blood draws less traumatic for children could go a long way to making their whole hospital experience better. We’re looking forward to working with Velano Vascular to see how this technology can help improve care for the kids we treat,” said Ann-Christine Duhaime, MD, NEPDC Co-Director and Director of the Pediatric Neurosurgery Department at Massachusetts General Hospital.
After a successful early engagement with Velano Vascular and their product, PIVO™, an FDA cleared device that makes inpatient blood draws a seamless and stress-free experience by reducing the number of sticks for blood collection, NEPDC will continue to support Velano Vascular in their efforts to engineer the device for use in smaller children and infants.
“We are honored to act as collaborators with NEPDC and the FDA in pursuit of a shared vision to eliminate the pain and anxiety that kids so closely associate with this necessary medical procedure,” said Velano Vascular CEO Eric M. Stone. “With PIVO, pediatric blood draws can become a less stressful, more pleasant experience for both children and their parents.”
NEPDC offers commercialization resources for pediatric medical devices through a seed grant program made possible through funds from the FDA Office of Orphan Product Development.
About New England Pediatric Device Consortium (NEPDC)
NEPDC is a non-profit consortium that provides infrastructure, expert consultation to innovators, and execution of technology translation and commercialization of pediatric technologies. For further information, visit www.NEPDC.org.
About Velano Vascular
Velano Vascular is committed to reducing the pain, risk, and inefficiencies of vascular access and blood collection practices. Velano Vascular’s PIVO device enables blood draws from Peripheral IV catheters, aiming to enable more compassionate care for hospital inpatients, a safer practice for caregivers, and a more financially responsible alternative for health systems. Velano Vascular is backed by First Round Capital, Griffin Hospital, Kapor Capital, Safeguard Scientifics, Sutter Health, The Children’s Hospital of Philadelphia (CHOP), White Owl Capital, and a number of health-industry veterans. Company collaborators include several of the leading hospital systems in the United States. More information is available at www.velanovascular.com and @velanovascular.